Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases

AIDS Research and Human Retroviruses

Volumn 23, Issue 6, 2007, Pages 801-804

  Maida, Ivana ^a,b   Soriano, Vincent ^a   Barreiro, Pablo ^a   Rivas, Pablo ^a   Labarga, Pablo ^a   Núñez, Marina ^a,c  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSITY OF SASSARI   (Italy)

^c WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMINOTRANSFERASE; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; ELASTOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL;

ADULT; ALANINE TRANSAMINASE; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; MALE; RNA, VIRAL;

EID: 34248589232     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0085     Document Type: Article

References (25)

1. Mathurin P, Moussalli J, Cadranel J, et al.: Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998;27:868-872.
2. Martinot-Peignoux M, Boyer N, Cazals-Hatem D, et al.: Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA. Hepatology 2001;34:1000-1005.
3. Okanoue T, Makiyama A, Nakayama M, et al.: A follow-up study to determine the value of liver biopsy and need for antiviral therapy for hepatitis C virus carriers with persistently normal serum aminotransferases. J Hepatol 2005;43:599-605.
4. Lauer G and Walker B: Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
5. Ziol M, Handra-Luca A, Kettaneh A, et al.: Non-invasive assessment of liver fibrosis by stiffness measurement: A prospective multicentre study in patients with chronic hepatitis C. Hepatology 2005;41:48-54.
6. Castéra L, Vergniol J, Foucher J, et al.: Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.
7. De Lédinghen V, Douvin C, Kettaneh A, et al.: Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006;41:175-179.
8. Collettta C, Smirne C, Fabris C, et al.: Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005;42:838-845.
9. Puoti C, Castellacci R, and Montagnese F: Hepatitis C carriers with normal aminotransferase levels: Healthy people or true patients? Digest Liver Dis 2000;32:634-643.
10. Puoti C, Castellacci R, Montagnese F, et al.: Histological and virological features and follow-up of HCV carriers with normal aminotransferase levels: The Italian Study of the Asymptomatic C Carriers (ISACC). J Hepatol 2002;37:117-123.
11. Puoti C: HCV carriers with persistently normal aminotransferase levels: Normal does not always mean healthy. J Hepatol 2003;38:529-532.
12. Gholson C, Morgan K, Catiis G, et al.: Chronic hepatitis C with normal aminotransferase levels: A clinical histological study. Am J Gastroenterol 1997;92:1788-1792.
13. Conry-Cantilena C, VanRaden M, Gibble J, et al.: Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996;334:1691-1696.
14. Alberti A, Noventa F, Benvegnù L, Boccato S, and Gatta A: Prevalence of liver disease in a population of asymptomatic persons with hepatitis C virus infection. Ann Intern Med 2002;137:961-964.
15. Fonquernie L, Serfaty L, Charrois A, et al.: Significance of hepatitis C virus coinfection with persistently normal alanine aminotransferase levels in HIV-1-infected patients. HIV Med 2004;5:385-390.
16. Uberti-Foppa C, de Bona A, Galli L, et al.: Liver fibrosis in HIV-positive patients with hepatitis C virus: Role of persistently normal alanine aminotransferase levels. J Acquir Immune Defic Syndr 2006;41:63-67.
17. Persico M, Persico E, Suozzo R, et al.: Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels. Gastroenterology 2000;118:760-764.
18. Maida I, Babusieri S, Selva C, et al.: Liver enzyme elevation in hepatitis C virus (HCV)-HIV co-infected patients prior to and after initiating HAART: Role of HCV genotypes. AIDS Res Human Retroviruses 2006;22:139-143.
19. Puoti C, Magrini A, Stati T, et al.: Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine aminotransferase levels. Hepatology 1997;26:1393-1398.
20. Poynard T, Bedossa P, Opolon P, et al.: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;346:825-832.
21. Benhamou Y, Bochet M, di Martino V, et al.: Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-1058.
22. Martin-Cabonero L, Benhamou Y, Puoti M, et al.: Incidence and predictors of severe liver fibrosis in HIV infected patients with chronic hepatitis C - a European collaborative study. Clin Infect Dis 2004;38:128-133.
23. Nuñez M and Soriano V: Hepatitis C virus (HCV) genotypes and disease progression in HIV/HCV-coinfected patients. J Infect Dis 2005;191:1-3.
24. Yoo T, Donfield S, Lai A, et al.: Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis 2005;191:4-10.
25. Barreiro P, Martin-Carbonero L, Nuñez M, et al.: Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C: Assessment using transient elastometry and role of HCV genotype 3. Clin Infect Dis 2006;42:1032-1039.